Wegovy, Mounjaro or Ozempic: FDA warns of risk of serious eye condition associated with these medications

The US Food and Drug Administration (FDA) has identified a potentially increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients using GLP-1 receptor agonist medications, including Ozempic, Wegovy, Mounjaro, and Zepbound. This serious condition, which can cause blindness due to restricted blood flow to the optic nerve, has prompted the FDA to request that manufacturers add it to their product warning labels. The European Medicines Agency (EMA) notes that NAION affects approximately one in every 10,000 people taking semaglutide, the active ingredient in Ozempic and Wegovy.